Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 124

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 124
---
 Purchase Agreement, we agreed not to enter into any agreement to issue or announce the issuance
or proposed issuance of any Common Shares or Common Share equivalents for a period of 45 days following the closing of the offering, subject
to certain customary exceptions. We have also agreed that from the date of the March Purchase Agreement until one year after the closing
date of the offering, that we shall not enter into an agreement to effect any issuance by us or any of our subsidiaries of Common Shares
or Common Share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross
proceeds to us of $1,750,000. We intend to use the net proceeds from the offering for working capital and general corporate purposes.

On June 28, 2024, we
entered into a securities purchase agreement providing for the issuance in a registered direct offering of 81,944 Common Shares at a purchase
price of $9.60 per share. In addition, the investors in the offering received unregistered warrants to purchase up to an aggregate of
81,944 Common Shares at an exercise of $9.60 per share in a concurrent private placement. The common warrants were immediately exercisable
upon issuance and expire five years following the date of issuance. The agreement includes customary representations, warranties,
and indemnification provisions. We agreed not to issue or announce the issuance of any Common Shares or equivalents for 15 days post-closing,
with certain exceptions, and not to engage in variable rate transactions for one-year post-closing. The offering generated gross proceeds
of approximately $786,660.

On September 16, 2024,
we entered into a warrant amendment agreement with an institutional investor to amend warrants to purchase up to 172,836 Common Shares,
adjusting the definition of a “Fundamental Transaction” and the exercise price to CHF 0.80 (the “September Warrant Amendment”).
In exchange for the September Warrant Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.02, and
following the Company increasing its authorized Common Shares, issued to the investor, pre-funded warrants to purchase up to 191,431 shares
of Common Shares.

On October 9, 2024, we
entered into a securities purchase agreement with certain accredited investors. Under this agreement, we issued and sold 806,452 Common
Shares and warrants to purchase an additional 806,452 Common Shares, at a combined purchase price of